Posted: 16 April 2024
Adherium Limited ( “Adherium” or “the Company”; ASX:ADR), a global leader in digital health technologies addressing chronic respiratory diseases, is pleased to announce that its innovative Hailie® Smartinhaler® has received clearance from the U.S. Food and Drug Administration (FDA) for use with AstraZeneca’s Airsupra® and Breztri® inhalation devices. Airsupra is the first FDA approved rescue medication for asthma patients and Breztri is a triple combination for COPD patients.
This development marks a significant milestone in the management of asthma and chronic obstructive pulmonary disease (COPD), offering patients and healthcare providers enhanced monitoring capabilities and personalised treatment approaches. This new compatibility with Breztri® gives Adherium 100% coverage for triple therapy inhalers in the US.
Airsurpa® and Breztri®, developed by AstraZeneca®, are at the forefront of respiratory care, providing patients with advanced treatment options. Airsupra® is revolutionising rescue medication, offering a long awaited, as-needed rescue (ICS/SABA), forever changing asthma management. Breztri®, on the other hand, has demonstrated significant benefits in reducing exacerbations in COPD patients, underscoring its role in advancing treatment standards.
The option to combine Adherium’s Hailie® Smartinhaler® with these medications empowers patients and clinicians with real-time data and insights into their medication usage patterns and inhaler technique feedback, fostering better adherence and enabling tailored treatment regimens. This personalised approach to management is expected to enhance overall treatment efficacy and dramatically improve patient quality and outcomes.
Dr. Bill McCann, a prominent Allergist and long-time advocate for advanced respiratory care solutions, commented on the launch:
“The combination of the Hailie® Smartinhaler® with Airsupra® and Breztri® devices represents a leap forward in our ability to treat and manage asthma and COPD. This integration allows for a more nuanced understanding of patient needs and the ability to adjust treatments in real-time, which is invaluable in achieving optimal patient outcomes.”
Dr. Paul Mastoridis, CEO of Adherium, shared his vision for the future:
“Our mission at Adherium has always been to revolutionise the way respiratory conditions are managed. By securing FDA clearance for our Smartinhaler® with Airsupra® and Breztri®, we’re bringing that vision to life, offering patients and healthcare providers a powerful tool in the fight against chronic respiratory diseases. This is just the beginning of our journey to transform respiratory care.”
